Martin Dietrich, MD, PhD, separates an agent working in the brain from an agent acting on the brain, and explains that ...

Geoffrey Y. Ku, MD discusses two of the most active areas of investigation in the perioperative management of gastric and ...

Bispecific administration is already routine in independent community oncology, with 91.4% of responding practices delivering therapy and 5.4% planning implementation within 12 months. Office-based ...

Preview the 2026 International Myeloma Society meeting: the IMS/IMWG cure consensus, plenary session phase 3 trials, and new bispecific/CAR T myeloma findings. The 23rd International Myeloma Society ...

CAR T and bispecific T-cell engagers move earlier in blood cancer care, reshaping sequencing and expanding access beyond academic centers. T-cell–based immunotherapies have transformed the treatment ...

NCCN recommends rusfertide across PV risk strata as Category 1, uniquely spanning low- and high-risk disease in the updated ...

Martin Dietrich, MD, PhD, says he manages neurologic adverse events reactively rather than proactively, because he cannot ...

The imlunestrant label includes a warning and precaution for embryo-fetal toxicity, and the abemaciclib label includes ...

Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care. Chronic lymphocytic leukemia (CLL) treatment has undergone ...

David DiBardino, MD, explains how a hafnium compound is being tested alongside chemoradiation and durvalumab to address low ...

Fast Track designation supports expedited development of LYT-200 plus an HMA in R/R HR-MDS following prior HMA relapse or ...

Gandara, MD, explains why KRAS G12C predicts immunotherapy benefit in non–small cell lung cancer and what EMPOWER-Lung 1 means for trial design. He noted that most earlier analyses lumped KRAS ...